Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer
© Nair et al; licensee BioMed Central Ltd. 2011
Received: 20 April 2011
Accepted: 25 September 2011
Published: 25 September 2011
Specific properties of amphiphilic copolymeric micelles like small size, stability, biodegradability and prolonged biodistribution have projected them as promising vectors for drug delivery. To evaluate the potential of δ-valerolactone based micelles as carriers for drug delivery, a novel triblock amphiphilic copolymer poly(δ-valerolactone)/poly(ethylene glycol)/poly(δ-valerolactone) (VEV) was synthesized and characterized using IR, NMR, GPC, DTA and TGA. To evaluate VEV as a carrier for drug delivery, doxorubicin (DOX) entrapped VEV micelles (VEVDMs) were prepared and analyzed for in vitro antitumor activity.
VEV copolymer was successfully synthesized by ring opening polymerization and the stable core shell structure of VEV micelles with a low critical micelle concentration was confirmed by proton NMR and fluorescence based method. Doxorubicin entrapped micelles (VEVDMs) prepared using a modified single emulsion method were obtained with a mean diameter of 90 nm and high encapsulation efficiency showing a pH dependent sustained doxorubicin release. Biological evaluation in breast adenocarcinoma (MCF7) and glioblastoma (U87MG) cells by flow cytometry showed 2-3 folds increase in cellular uptake of VEVDMs than free DOX. Block copolymer micelles without DOX were non cytotoxic in both the cell lines. As evaluated by the IC50 values VEVDMs induced 77.8, 71.2, 81.2% more cytotoxicity in MCF7 cells and 40.8, 72.6, 76% more cytotoxicity in U87MG cells than pristine DOX after 24, 48, 72 h treatment, respectively. Moreover, VEVDMs induced enhanced apoptosis than free DOX as indicated by higher shift in Annexin V-FITC fluorescence and better intensity of cleaved PARP. Even though, further studies are required to prove the efficacy of this formulation in vivo the comparable G2/M phase arrest induced by VEVDMs at half the concentration of free DOX confirmed the better antitumor efficacy of VEVDMs in vitro.
Our studies clearly indicate that VEVDMs possess great therapeutic potential for long-term tumor suppression. Furthermore, our results launch VEV as a promising nanocarrier for an effective controlled drug delivery in cancer chemotherapy.
In spite of the current advances in cancer, chemotherapy still faces the major problem of lack of selectivity of anticancer drugs towards neoplastic cells . The efficacy of chemotherapy is decided by maximum tumor cell killing effect during the tumor growth phase and minimum exposure of healthy cells to the cytotoxic agent. Continuous and steady infusion of the drug into the tumor interstitium is also desirable to exterminate the proliferating cells, to finally cause tumor regression. Advances in nanotechnology have resulted in the evolution of a variety of nano-sized carriers for controlled and targeted delivery of chemotherapeutics [2–4]. Moreover, recent advances in polymer based micelles have opened new frontiers for drug delivery [5, 6] and tumor targeting .
Amphiphilic block copolymers have the tendency to self-assemble into micelles in a selective solvent because of the presence of both, hydrophilic as well as hydrophobic segments [8, 9]. These polymeric micelles consist of a core and shell like structure, in which the inner core is the hydrophobic part and can be utilized for encapsulation of drugs, whereas the hydrophilic block constituting the outer shell provides stabilization. The potential of polymeric micelles as drug carriers lie in their unique properties like small size, prolonged circulation, biodegradability and thermodynamic stability [10, 11]. Moreover, these micelles have the ability to preferentially target tumor tissues by enhanced permeability and retention effect due to the small size of the carrier molecule which facilitates the entry within biological constraints proving their superiority over other particulate carriers [12, 13]. Another important characteristic of these micelles is the presence of water compatible polymers like polyethylene glycol (PEG) which improves the bioavailability of these drug delivery systems [14, 15]. PEG not only saturates these polymeric particles with water by making them soluble, but also prevents opsonization of these nanocarriers by providing steric stabilization against undesirable aggregation and non-specific electrostatic interactions with the surroundings [16, 17]. This has resulted in an extensive study of drug formulations using copolymeric micelles with enhanced antitumor efficacy [18–20]. Although, a number of polyester based copolymers like caprolactone, valerolactone and lactides have been studied [21–23], serious investigations on δ-valerolactone based copolymeric micelles for drug delivery applications are scarcely reported in literature. For example, doxorubicin based copolymeric micelles have been investigated [24, 25], but the potential of δ-valerolactone and PEG based micelles as carriers for controlled delivery is yet to be explored. Doxorubicin (DOX), an anthracycline antibiotic, is a drug used in the treatment of a large spectrum of cancers especially breast, ovarian, brain and lung cancers . However, its therapeutic potential is limited due to its short half life  and severe toxicity to healthy tissues resulting in myelosuppression and cardiac failure [28, 29].
Hence, the aim of this work was to use a δ-valerolactone based amphiphilic block copolymer to develop a novel micellar controlled delivery system for DOX and analysis of its anticancer activity. The present study involves the synthesis of a triblock copolymer of δ-valerolactone, poly δ-valerolactone)/poly(ethylene glycol)/poly(δ-valerolactone) (VEV) by ring opening polymerization and characterization using IR, NMR and GPC. The thermal stability of VEV was analyzed using DTA and TGA. Micellization followed by biocompatibility studies of the copolymer were done to evaluate its potential as a carrier for drug delivery. DOX entrapped VEV micelles (VEVDMs) were prepared and characterized using TEM and the in vitro release kinetics at two different pH. Their biological evaluation was done in two different cancer cell lines, breast adenocarcinoma (MCF7) and glioblastoma (U87MG). Cellular uptake of micelles was observed and compared to free DOX using confocal microscopy and FACS. Furthermore, the antiproliferative activity was analyzed by MTT assay, Annexin V-FITC staining and western blot analysis followed by alterations in cell division cycle.
Synthesis and characterization of triblock copolymer
Micellization and characterization
Characterization of VEV micelles
Micelle size (nm)
83 ± 2.5
0.17 ± 0.008
1.16 ± 0.03
Preparation and properties of DOX loaded copolymeric micelles (VEVDMs)
Characterization of doxorubicin loaded VEV micelles (VEVDMs)
56.2 ± 2.4
90.4 ± 3.5
80.9 ± 4.0
0.173 ± 0.01
VEVDMs showed enhanced cellular uptake
Micellar DOX of non-toxic VEV copolymer exhibited better in vitro cytotoxicity with smaller IC50 values
IC50 values (in equivalent μM DOX) of MCF7 and U87MG cells cultured with VEVDMs vs. free doxorubicin in 24, 48, 72 h
Incubation time (h)
IC50 MCF7 cells (μM)
IC50 U87MG cells (μM)
Annexin V-FITC showed enhanced apoptosis by VEVDMs
Better PARP cleavage induced by VEVDMs
Induction of cell cycle arrest by low concentrations of VEVDMs
These micelles were further assessed for biological evaluation of VEV as a carrier using doxorubicin (DOX) as the model drug.
The modified single emulsion solvent evaporation method adopted for the preparation of DOX loaded VEV micelles (VEVDMs) not only proved to be simple and efficient for the fabrication of drug entrapped micelles but also gave particles in the size range of 90 nm (Figure 6) with high encapsulation efficiency and yield (Table 2). Here, the particle size is a very important physical parameter because it directly affects the cellular uptake capability. The analysis of DOX release from micelles showed a biphasic pattern with first phase of slight burst release followed by second phase of sustained release continuing over a period of two weeks (Figure 7). The drug release from micelles showed pH dependence which might be due to the variation in the hydrolysis of ester chain and DOX solubility with changing pH [33, 34]. This slow and sustained release from VEVDMs could be more desirable for the delivery of DOX to solid tumors in vivo. Although, actual application need the evaluation of these micelles in animal models, sustained drug release from VEVDMs supports the idea of using VEV copolymer based micelles for controlled delivery of anticancer agents.
Enhanced intracellular uptake of VEVDMs by MCF7 and U87MG cells as shown by confocal images and FACS (Figure 8) may be attributed to the small size of drug loaded micelles with PEG on their surface. Since few studies have reported that based on biocompatibility ε-caprolactone based copolymers are better for drug delivery applications in comparison to δ-valerolactone [15, 17], we analyzed the cytotoxicity of VEV and found that the copolymer showed no cytotoxicity at concentrations up to 0.1 mg/ml even on incubation of 3 days (Figure 9). Since lesser concentrations of drug loaded micelles are for administration, no issues of biocompatibility are expected. Moreover, after dilution with large volume of body fluid in vivo, 0.1 mg/ml represents a much higher intravenous material dose than required for in vivo drug delivery. Therefore, VEV can be considered to be non toxic and biocompatible. However, intracellular toxicity evaluation of VEVDMs induced higher cell killing in both cells in a concentration and time dependent manner (Figure 10). Considerable lower IC50 values of VEVDMs (Table 3) might be due to the enhanced cellular uptake accompanied by a slight burst release which showed acceleration in acidic conditions. Furthermore, higher shift in Annexin V-FITC fluorescence (Figure 11) and intensity of cleaved PARP (Figure 12) which are clear indicators of apoptosis as reported in our earlier studies , confirms that VEVDMs are more effective in inducing cell death. In agreement with previous reports of DOX induced DNA damage occurring predominantly in the G2/M phase of cell cycle , VEVDMs even at half the concentration of free DOX induced comparable G2/M arrest accompanied by a higher S phase arrest (Figure 13). Since cell cycle arrest is doxorubicin concentration and exposure time dependent with higher concentrations inducing delayed S phase transit [37, 38], higher S phase arrest by half dose of VEVDMs may serve the same purpose as done by a double amount of free DOX. Thus, the higher apoptosis induced by VEVDMs might also be attributed to the fate of cell cycle arrest. Another very important thing to be noted is that VEVDMs showed better antitumor activity against both the cell lines irrespective of their nature , which suggests their use against a variety of tumors.
Hence, our study clearly indicates the challenging potential of VEVDMs for cancer treatment with enhanced micellar stability imparted by the high hydrophobic nature of δ-valerolactone. The superior antitumor efficacy may be accounted on the basis of higher cellular uptake, DOX release in acidic conditions and cell cycle arrest. Although, further evaluation of VEVDMs in vivo model is required, these PEGylated micelles certainly possess the tendency to accumulate in solid tumors with increased bioavailability [40, 41] to deliver the anticancer agent for a long-lasting tumor containment.
A novel δ-valerolactone and PEG based triblock copolymer was synthesized and characterized for drug delivery applications. VEV prepared by ring opening polymerization showed good micelle formation tendency and no cellular toxicity. To evaluate VEV as a carrier, DOX was successfully loaded in VEV using a modified single emulsion method with high encapsulation efficiency and yield. DOX release from VEVDMs continued for more than two weeks and was found to be pH dependent. VEVDMs obtained in the size range of 90 nm showed enhanced cellular uptake efficiency and much lower IC50 values in comparison to pristine DOX. Moreover, the efficiency of DOX micelles to induce apoptosis accompanied by significant cell cycle arrest supports the idea of using VEVDMs against malignancy. Although additional studies are required to evaluate the in vivo behavior of VEV, our results confirm the potential of VEVDMs in chemotherapy and VEV as a carrier for future applications in drug delivery.
δ-valerolactone (VL), doxorubicin hydrochloride (DOX), stannous octoate, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), Pluronic F-68, Ribonuclease A, 1,6-diphenyl-1,3,5-hexatriene (DPH) and Annexin V apoptosis detection kit were purchased from Sigma-Aldrich, Steinheim, Germany. Polyethylene Glycol 2000 (PEG) was obtained from Merck Schuchardt OHG, Germany. Poly (ADP-ribose) polymerase (PARP) was bought from cell signaling and enhanced chemiluminescence kit from GE Amersham. Human breast adenocarcinoma (MCF7) and glioblastoma (U87MG) cells were provided from ATCC (USA) and maintained in DMEM medium containing 10% fetal bovine serum (Sigma, USA) and 1% antibiotic antimycotic cocktail (Himedia, India). All solvents were of analytical grade.
Synthesis of poly (δ-valerolactone)/poly (ethylene glycol)/poly (δ-valerolactone) (VEV) copolymer
The triblock copolymer, VEV was synthesized by ring opening polymerization of PEG and VL in the presence of stannous octoate as catalyst as reported , with some modifications. In a typical procedure, PEG and VL monomers (molar ratio 1:200) along with stannous octoate (0.005 mol %) were added to the reaction vessel and placed under nitrogen in an oil bath at 110°C with magnetic stirring for 24 h. The resulting mixture was cooled to room temperature, dissolved in dichloromethane and precipitated in an excess amount of cold ether to remove residual monomers. Purification of the copolymer was achieved by the dissolution/precipitation method with dichloromethane and ether, followed by filtration and drying in vacuum.
Characterization of VEV copolymer
To characterize VEV, Fourier transform infrared (FT-IR) spectra were measured by FT-IR spectrometer (Nicolet 5700) using potassium bromide (KBr) pellets. Proton nuclear magnetic resonance 1H spectra (NMR) were obtained using Bruker 500 MHz with deuterated chloroform (CDCl3) or water (D2O) as solvent. To analyze the molecular weight, gel permeation chromatography (GPC) measurements were carried out on a Waters 515 liquid chromatography system equipped with two Waters Styragel HR 5ETHF columns and a Waters 2414 refractive index detector using tetrahydrofuran (THF) as the eluent (1.0 ml/min). In addition, thermal stability of the polymer was measured by differential thermal analysis (DTA) and thermogravimetric analysis (TGA) using SDT-2960, TA Instruments Inc under nitrogen flow at a scanning rate of 10°C min-1.
Micellization and characterization
VEV polymeric micelles were prepared by a known precipitation method . Briefly, 100 mg of polymer dissolved in 10 ml of acetone was added to 50 ml aqueous media and stirred overnight at room temperature to remove the organic solvent. The polymeric micelles were then lyophilized and resuspended before every analysis. The size of micelles was measured using a particle size analyzer (Beckman Coulter Delsa Nano Particle Analyzer). The critical micelle concentration (CMC) of VEV micelles was determined by fluorescence based method using DPH as a probe . In brief, VEV aqueous solutions were added to DPH solution (0.4 mM), such that the final concentration of copolymer ranged from 0.001-1 wt%. The samples were equilibrated overnight at room temperature and UV absorption was recorded at 365 nm on a UV-VIS spectrophotometer (Perkin Elmer, USA). The critical micelle concentration (CMC) was calculated on the basis of absorption vs. logarithmic polymer concentrations. Micelles were also analyzed by 1H NMR using deuterated water as a solvent.
Preparation and characterization of DOX loaded VEV micelles (VEVDMs)
In a novel method for preparing drug entrapped micelles using a triblock copolymer, single emulsion solvent evaporation method was adopted. Briefly, DOX (1:100 w/w) dissolved in methanol (1:10 v/v) was added to VEV solution in acetone to form the organic phase, which on addition to an aqueous phase containing Pluronic F-68 (1%) gave emulsion containing micelles. This emulsion after sonication was subjected to overnight stirring at room temperature to get micellar suspension. VEVDMs in dry powder form were obtained after centrifugation followed by lyophilization.
Size analysis of VEVDMs was done using particle size analyzer (Beckman Coulter Delsa Nano Particle Analyzer) and images were taken using a transmission electron microscope (TEM, JEOL 1011, Japan). To calculate the drug content in micelles, weighed amount of dried drug loaded micelles were dissolved in DMSO (dimethyl sulphoxide) and the drug amount was calculated according to a standard curve obtained using DMSO solutions of known concentrations of free DOX by UV spectrophotometer (Perkin Elmer, USA) at the detection wavelength 480 nm. The encapsulation efficiency was expressed as the ratio of DOX in micelles to the initial amount of drug used. The yield corresponds to the ratio of amount of micelles recovered to the total amount of polymer and drug used in formulation.
In vitro drug release
DOX loaded micelles were dispersed in distilled water (1 mg/ml) and then placed in a dialysis bag (MW cut off: 3500). The dialysis bag was then immersed in 15 ml of buffer solutions with pH 5.0 (acidic) and 7.4 (physiological) and incubated at 37°C. At specific time intervals, the drug released solution was replaced with equal amount of fresh media and the amount of DOX released was analyzed using UV-vis spectrophotometer at 480 nm. The release kinetics at two different was compared to that of free DOX.
Cellular uptake studies
To visualize the cellular uptake of drug-loaded micelles, cells were grown on cover slips placed in 24 well plates. After 24 hours cells were treated with 1 μM DOX formulations and incubated for 2 h. The cells were washed, mounted and examined under a confocal laser scanning microscope (CLSM, Leica DMI 4000B) at a magnification of 60× for intracellular DOX fluorescence. Furthermore, the intensity of DOX fluorescence on cellular uptake was analyzed using flow cytometry (FACS Aria, BD, USA). Cells seeded in six-well culture plates (5 × 104) after 24 h incubation, were treated with 1 μM DOX formulations. After exposure of 2 h, the cells were washed with cold PBS three times, harvested using trypsin-EDTA and analyzed for internal fluorescence of DOX using flow cytometer.
To assess the cytotoxicity of empty VEV micelles, free DOX and VEVDMs, 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay was performed . Briefly, human breast adenocarcinoma (MCF7) and gliomablastoma (U87MG) cells were seeded (5.0 × 103/well) and incubated for 24 h in 96-well plates. Cells were incubated with various concentrations of VEV, free DOX and VEVDMs as indicated and incubated for 24, 48 and 72 h, respectively. Following treatment the amount of formazan crystals formed was measured after 4 h of MTT addition (10% v/v) by adding isopropyl alcohol and OD measurement at 570 nm. The relative cell viability in percentage was calculated as (Atest/Acontrol) × 100.
Annexin V-FITC staining
To examine cell apoptosis induced by DOX formulations, Annexin V-FITC stain assay was performed on both the cell lines . Briefly, cells cultured with or without drug (1 μM) for 24 h were washed in cold PBS and resuspended in binding buffer. Afterwards, cells were stained with FITC-labeled annexin using Annexin V-FITC Apoptosis Detection Kit according to the manufacturer's instructions and a flow cytometric analysis was then carried out using FACS Aria (Special order system, BD, USA).
Western blot analysis
2× 106 cells were seeded in 100-mm culture plates and treatments containing 3 μM DOX was given for 24 h. Cells were then lysed and the total protein content was measured using Bradford's reagent. 50 μg of total protein was loaded for SDS-PAGE. Immunoblotting was carried out using antibodies specific for PARP and detected using enhanced chemiluminescence (ECL) method .
Cell cycle analysis
For flow cytometric analysis, 106 cells were seeded in six-well culture dishes and given treatment of 0.05 μM VEVDMs and 0.1 μM free DOX for 24 h. Cells were harvested and fixed with 70% ethanol for 1 h. The fixed cells were then given RNAse A (100 mg/ml) treatment for 1 h at 37°C followed by propidium iodide (10 mg/ml) incubation for 15 min. Finally, cells were analyzed using FACS Aria (Special order system, BD, USA) .
All the measurements were done in three or more replicates. The results are expressed as arithmetic mean ± standard error on the mean (S.E.M). For cytotoxicity experiments the normalization of the data was done by considering the mean value of the untreated samples as 100%. All other data points were expressed as percentage of the control. Statistical difference (*p < 0.05, **p < 0.01) were calculated using GraphPad Instat 3.
Authors are thankful to National Institute of Interdisciplinary Sciences and Technology, Kerala for NMR studies and CSIR, New Delhi for providing Research Fellowship to Lekha Nair K.
- Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of Clinical Oncology. 2007, 25: 146.View Article
- Haley B, Frenkel E: Nanoparticles for drug delivery in cancer treatment. Urologic oncology. 2008, 26: 57-10.1016/j.urolonc.2007.03.015.View Article
- Nair KL, Jagadeeshan S, Nair SA, Kumar GSV: Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. International Journal of Nanomedicine. 2011, 6: 1685-1697.
- Sahoo SK, Parveen S, Panda JJ: The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnology, Biology and Medicine. 2007, 3: 20-31. 10.1016/j.nano.2006.11.008.View Article
- Torchilin VP: Block copolymer micelles as a solution for drug delivery problems. Expert opinion on therapeutic patents. 2005, 15: 63-75. 10.1517/135437184.108.40.206.View Article
- Torchilin VP: Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical research. 2007, 24: 1-16.View Article
- Kedar U, Phutane P, Shidhaye S, Kadam V: Advances in Polymeric Micelles for Drug Delivery and Tumor Targeting. Nanomedicine: Nanotechnology, Biology and Medicine. 2010
- Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC: Block copolymer micelles: preparation, characterization and application in drug delivery. Journal of Controlled Release. 2005, 109: 169-188. 10.1016/j.jconrel.2005.09.034.View Article
- Tyrrell ZL, Shen Y, Radosz M: Fabrication of Micellar Nanoparticles for Drug Delivery Through the Self-Assembly of Block Copolymers. Progress in Polymer Science. 2010
- Kim SY, Cho SH, Chu L, Lee YM: Biotin-Conjugated Block Copolymeric Nanoparticles as Tumor-Targeted Drug Delivery Systems. Macromolecular Research. 2007, 15: 646-10.1007/BF03218945.View Article
- Kim SY, Lee YM, Baik DJ, Kang JS: Toxic characteristics of methoxy poly (ethylene glycol)/poly (epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials. 2003, 24: 55-10.1016/S0142-9612(02)00248-X.View Article
- Lukyanov AN, Gao Z, Mazzola L, Torchilin VP: Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharmaceutical research. 2002, 19: 1424-1429. 10.1023/A:1020488012264.View Article
- Weissig V, Whiteman KR, Torchilin VP: Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharmaceutical research. 1998, 15: 1552-1556. 10.1023/A:1011951016118.View Article
- Hu Y, Xie J, Tong YW, Wang CH: Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. Journal of Controlled Release. 2007, 118: 7-17. 10.1016/j.jconrel.2006.11.028.View Article
- Lin WJ, Chen YC, Lin CC, Chen CF, Chen JW: Characterization of pegylated copolymeric micelles and in vivo pharmacokinetics and biodistribution studies. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2006, 77: 188-194.View Article
- Lin WJ, Juang LW, Lin CC: Stability and release performance of a series of pegylated copolymeric micelles. Pharmaceutical research. 2003, 20: 668-673. 10.1023/A:1023215320026.View Article
- Lin WJ, Juang LW, Wang CL, Chen YC, Lin CC, Chang KL: Pegylated Polyester Polymeric Micelles as a Nano-carrier: Synthesis, Characterization, Degradation, and Biodistribution. Journal of Experimental & Clinical Medicine. 2010, 2: 4-10. 10.1016/S1878-3317(10)60002-2.View Article
- Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T: NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. British journal of cancer. 2005, 92: 1240-1246. 10.1038/sj.bjc.6602479.View Article
- Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ: Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clinical cancer research. 2004, 10: 3708-10.1158/1078-0432.CCR-03-0655.View Article
- Le Garrec D, Gori S, Luo L, Lessard D, Smith DC, Yessine MA, Ranger M, Leroux JC: Poly (N-vinylpyrrolidone)-block-poly (D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. Journal of Controlled Release. 2004, 99: 83-101. 10.1016/j.jconrel.2004.06.018.View Article
- Liu J, Zeng F, Allen C: In vivo fate of unimers and micelles of a poly (ethylene glycol)-block-poly (caprolactone) copolymer in mice following intravenous administration. European Journal of Pharmaceutics and Biopharmaceutics. 2007, 65: 309-319. 10.1016/j.ejpb.2006.11.010.View Article
- Wang F, Bronich TK, Kabanov AV, Rauh RD, Roovers J: Synthesis and Characterization of Star Poly (-caprolactone)-b-Poly (ethylene glycol) and Poly (l-lactide)-b-Poly (ethylene glycol) Copolymers: Evaluation as Drug Delivery Carriers. Bioconjugate chemistry. 2008, 19: 1423-1429. 10.1021/bc7004285.View Article
- Wang YC, Tang LY, Sun TM, Li CH, Xiong MH, Wang J: Self-Assembled Micelles of Biodegradable Triblock Copolymers Based on Poly (ethyl ethylene phosphate) and Poly (-caprolactone) as Drug Carriers. Biomacromolecules. 2007, 9: 388-395.View Article
- Shuai X, Ai H, Nasongkla N, Kim S, Gao J: Micellar carriers based on block copolymers of poly (-caprolactone) and poly (ethylene glycol) for doxorubicin delivery. Journal of Controlled Release. 2004, 98: 415-426. 10.1016/j.jconrel.2004.06.003.View Article
- Yang Y, Hua C, Dong CM: Synthesis, Self-Assembly, and In Vitro Doxorubicin Release Behavior of Dendron-like/Linear/Dendron-like Poly (-caprolactone)-b-Poly (ethylene glycol)-b-Poly (-caprolactone) Triblock Copolymers. Biomacromolecules. 2009, 10: 2310-2318. 10.1021/bm900497z.View Article
- Blum RH, Carter SK: Adriamycin. Annals of Internal Medicine. 1974, 80: 249-259.View Article
- Al-Shabanah OA, El-Kashef HA, Badary OA, Al-Bekairi AM, Elmazar M: Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacological Research. 2000, 41: 31-37. 10.1006/phrs.1999.0568.View Article
- Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD: Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer chemotherapy and pharmacology. 1990, 27: 13-19. 10.1007/BF00689270.View Article
- Rahman A, Joher A, Neefe JR: Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. British journal of cancer. 1986, 54: 401-408. 10.1038/bjc.1986.190.View Article
- Chang YC, Chu I: Methoxy poly (ethylene glycol)-b-poly (valerolactone) diblock polymeric micelles for enhanced encapsulation and protection of camptothecin. European Polymer Journal. 2008, 44: 3922-3930. 10.1016/j.eurpolymj.2008.09.021.View Article
- Lee H, Zeng F, Dunne M, Allen C: Methoxy poly (ethylene glycol)-block-poly (-valerolactone) copolymer micelles for formulation of hydrophobic drugs. Biomacromolecules. 2005, 6: 3119-3128. 10.1021/bm050451h.View Article
- Lin WJ, Wang CL, Juang LW: Characterization and comparison of diblock and triblock amphiphilic copolymers of poly (valerolactone). Journal of Applied Polymer Science. 2006, 100: 1836-1841. 10.1002/app.22580.View Article
- Gillies ER, Fréchet JMJ: pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate Chem. 2005, 16: 361-368. 10.1021/bc049851c.View Article
- Tang R, Ji W, Wang C: Amphiphilic Block Copolymers Bearing Ortho Ester Side Chains: pH Dependent Hydrolysis and Self Assembly in Water. Macromolecular bioscience. 2009, 10: 192-201.View Article
- Krishnan A, Hariharan R, Nair SA, Pillai MR: Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS) 1. Biochemical pharmacology. 2008, 75: 1924-1934. 10.1016/j.bcp.2008.02.013.View Article
- DiPaola RS: To Arrest or Not To G2-M Cell-Cycle Arrest. Clinical cancer research. 2002, 8: 3311.
- Barlogie B, Drewinko B, Johnston DA, Freireich EJ: The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Research. 1976, 36: 1975.
- O'Loughlin C, Heenan M, Coyle S, Clynes M: Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. European Journal of Cancer. 2000, 36: 1149-1160. 10.1016/S0959-8049(00)00071-X.View Article
- Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, Le Meins JF, Farooque A, Chandraiah G, Jain AK: The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly ([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials. 2010, 31: 2882-2892. 10.1016/j.biomaterials.2009.12.043.View Article
- Danhier F, Lecouturier N, Vroman B, Jér me C, Marchand-Brynaert J, Feron O, Préat V: Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. Journal of Controlled Release. 2009, 133: 11-17. 10.1016/j.jconrel.2008.09.086.View Article
- Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM: PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: Nanotechnology, Biology and Medicine. 2009, 5: 410-418. 10.1016/j.nano.2009.02.002.View Article
- Hu Y, Zhang L, Cao Y, Ge H, Jiang X, Yang C: Degradation Behavior of Poly (-caprolactone)-b-poly (ethylene glycol)-b-poly (-caprolactone) Micelles in Aqueous Solution. Biomacromolecules. 2004, 5: 1756-1762. 10.1021/bm049845j.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.